Inhibikase Therapeutics, Inc.
IKT
Price:
$1.2133
Market Cap:
$9.06M
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in ...[Read more]
Industry
Biotechnology
IPO Date
2020-12-23
Stock Exchange
NASDAQ
Ticker
IKT
The ROE as of September 2024 (TTM) for Inhibikase Therapeutics, Inc. (IKT) is -194.17%
According to Inhibikase Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -194.17%. This represents a change of 231.09% compared to the average of -58.64% of the last 4 quarters.
Inhibikase Therapeutics, Inc. (IKT) Historical ROE (quarterly & annually)
How has IKT ROE performed in the past?
The mean historical ROE of Inhibikase Therapeutics, Inc. over the last ten years is 19.38%. The current -194.17% ROE has changed -1101.76% with respect to the historical average. Over the past ten years (40 quarters), IKT's ROE was at its highest in in the March 2019 quarter at 223.19%. The ROE was at its lowest in in the June 2024 quarter at -97.31%.
Average
19.38%
Median
0.43%
Minimum
-173.34%
Maximum
276.68%
Inhibikase Therapeutics, Inc. (IKT) ROE by Quarter and Year
Discovering the peaks and valleys of Inhibikase Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 814.28%
Maximum Annual ROE = 276.68%
Minimum Annual Increase = -122.97%
Minimum Annual ROE = -173.34%
| Year | ROE | Change |
|---|---|---|
| 2023 | -173.34% | 103.64% |
| 2022 | -85.12% | 120.85% |
| 2021 | -38.54% | 31.06% |
| 2020 | -29.41% | -122.97% |
| 2019 | 128.01% | -53.73% |
| 2018 | 276.68% | 814.28% |
| 2017 | 30.26% | -34.94% |
Inhibikase Therapeutics, Inc. (IKT) Average ROE
How has IKT ROE performed in the past?
The current ROE of Inhibikase Therapeutics, Inc. (IKT) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-99.00%
5-year avg
-39.68%
10-year avg
19.38%
Inhibikase Therapeutics, Inc. (IKT) ROE vs. Peers
How is IKT’s ROE compared to its peers?
Inhibikase Therapeutics, Inc.’s ROE is greater than DiaMedica Therapeutics Inc. (-38.56%), greater than Milestone Pharmaceuticals Inc. (-165.26%), less than Seres Therapeutics, Inc. (313.56%), greater than Oncolytics Biotech Inc. (-114.55%), greater than scPharmaceuticals Inc. (-201.84%), greater than aTyr Pharma, Inc. (-56.83%), less than Sio Gene Therapies Inc. (0%), greater than Kaleido Biosciences, Inc. (-13.69%), less than Tempest Therapeutics, Inc. (0%), greater than AN2 Therapeutics, Inc. (-201.10%), greater than Miromatrix Medical Inc. (-54.72%), greater than PMV Pharmaceuticals, Inc. (-119.21%), greater than Anebulo Pharmaceuticals, Inc. (-21.96%), greater than Nutriband Inc. (-122.97%), greater than Quoin Pharmaceuticals, Ltd. (-76.31%), greater than Longeveron Inc. (-112.11%), greater than RenovoRx, Inc. (-246.98%), greater than Virax Biolabs Group Limited (-403.38%), greater than null (-115.10%),
| Company | ROE | Market cap |
|---|---|---|
| -38.56% | $194.50M | |
| -165.26% | $80.82M | |
| 313.56% | $157.72M | |
| -114.55% | $72.35M | |
| -201.84% | $273.16M | |
| -56.83% | $131.12M | |
| 0% | $30.70M | |
| -13.69% | $4.26K | |
| 0% | $34.51M | |
| -201.10% | $31.04M | |
| -54.72% | $92.95M | |
| -119.21% | $78.05M | |
| -21.96% | $54.20M | |
| -122.97% | $51.93M | |
| -76.31% | $2.51M | |
| -112.11% | $29.70M | |
| -246.98% | $26.15M | |
| -403.38% | $12.50M | |
| -115.10% | $0 |
Build a custom stock screener for Inhibikase Therapeutics, Inc. (IKT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibikase Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Inhibikase Therapeutics, Inc. (IKT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Inhibikase Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Inhibikase Therapeutics, Inc.'s ROE?
How is the ROE calculated for Inhibikase Therapeutics, Inc. (IKT)?
What is the highest ROE for Inhibikase Therapeutics, Inc. (IKT)?
What is the 3-year average ROE for Inhibikase Therapeutics, Inc. (IKT)?
What is the 5-year average ROE for Inhibikase Therapeutics, Inc. (IKT)?
How does the current ROE for Inhibikase Therapeutics, Inc. (IKT) compare to its historical average?